A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma
NCT ID: NCT02093000
Last Updated: 2018-02-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
201 participants
OBSERVATIONAL
2014-11-30
2018-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer
NCT03170284
An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
NCT01333007
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
NCT00451906
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
NCT01351415
A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
NCT00776698
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bevacizumab
Participants who have received the induction phase of 4-6 cycles of bevacizumab plus platinum doublet chemotherapy will be treated with bevacizumab as maintenance treatment, according to approved label and local reimbursement.
Bevacizumab
Participants will receive bevacizumab 7.5 milligrams per kilograms (mg/kg) intravenously according to bevacizumab summary of product characteristics/local labeling.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bevacizumab
Participants will receive bevacizumab 7.5 milligrams per kilograms (mg/kg) intravenously according to bevacizumab summary of product characteristics/local labeling.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant who received only 1 cycle of bevacizumab maintenance treatment
* Meet summary of product characteristics guidelines
Exclusion Criteria
* Pregnant or breast-feeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Orszagos Koranyi TBC es Pulmonologiai Intezet
Budapest, , Hungary
Semmelweis Egyetem X; Pulmonologiai Klinika
Budapest, , Hungary
Uzsoki Utcai Korhaz
Budapest, , Hungary
Debreceni Egyetem, Klinikai Kozpont, Tudogyogyaszati Klinika
Debrecen, , Hungary
Csongrad Megyei Mellkasi Betegsegek Szakkorhaza
Deszk, , Hungary
Veszprem Megyei Onkormanyzat Tudogyogyintezet
Farkasgyepű, , Hungary
Petz Aladar Megyei Oktato Korhaz
Győr, , Hungary
Bekes Megyei Tudokorhaz; I. Tudobelosztaly
Gyula, , Hungary
Bacs-Kiskun Megyei Korhaz
Kecskemét, , Hungary
Matrai Gyogyintezet
Mátraháza, , Hungary
Szabolcs-Szatmar-Bereg County Josa Andras Hospital; 1St Depatment of Pulmonary Medicine
Nyíregyháza, , Hungary
University of Pecs; 1St Department of Medicine
Pécs, , Hungary
Fejer Megyei Szent Gyorgy Korhaz
Székesfehérvár, , Hungary
Vas Megyei Markusovszky Korhaz ; Oncoradiology
Szombathely, , Hungary
Komárom-Esztergom Megyei; Szent Borbála Kórháza
Tatabánya, , Hungary
Tudogyogyintezet Torokbalint
Törökbálint, , Hungary
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML29261
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.